Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.
| Title | Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma. |
| Publication Type | Journal Article |
| Year of Publication | 2015 |
| Authors | Vij R, Wang M, Jagannath S, Niesvizky R, Jakubowiak AJ, Kavalerchik E, Huang M, Siegel DS |
| Journal | Leuk Lymphoma |
| Volume | 56 |
| Issue | 10 |
| Pagination | 2959-61 |
| Date Published | 2015 |
| ISSN | 1029-2403 |
| Keywords | Antineoplastic Agents, Biomarkers, Tumor, Drug Resistance, Neoplasm, Humans, Immunoglobulin Light Chains, Multiple Myeloma, Oligopeptides, Prognosis, Proteasome Inhibitors, Recurrence, Retrospective Studies, Treatment Outcome |
| DOI | 10.3109/10428194.2015.1020801 |
| Alternate Journal | Leuk. Lymphoma |
| PubMed ID | 25699653 |
